Michael Gelband’s Akero Therapeutics AKRO Stock Holding History

Michael Gelband’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-180,016	Closed	-$8.55M	–	1495
2025 Q3	$8.55M	Buy	+180,016	New	+$8.72M	0.09%	231
2025 Q2	–	Sell	-103,930	Closed	-$4.21M	–	1426
2025 Q1	$4.21M	Buy	103,930 +48,723	+88%	+$2.07M	0.04%	462
2024 Q4	$1.54M	Buy	55,207 +7,575	+16%	+$229K	0.01%	813
2024 Q3	$1.37M	Buy	47,632 +37,702	+380%	+$983K	0.01%	871
2024 Q2	$233K	Buy	+9,930	New	+$212K	﹤0.01%	1369
2024 Q1	–	Sell	-48,048	Closed	-$1.12M	–	1454
2023 Q4	$1.12M	Buy	+48,048	New	+$948K	0.01%	777

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Michael Gelband's AKRO Position: Q4 2025 in Review

Michael Gelband sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 180,016 shares — an estimated $8.55M sold.

Michael Gelband first reported a position in AKRO in Q4 2023 and held it in 6 quarters. The position peaked at $8.55M in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Michael Gelband reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Michael Gelband sold 180,016 Akero Therapeutics shares in Q4 2025, an estimated $8.55M.
Michael Gelband first reported a position in Akero Therapeutics in Q4 2023 and held it in 6 quarters.
Michael Gelband's Akero Therapeutics position peaked at $8.55M in Q3 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.